ScripThe market for BCMA-directed therapies to treat multiple myeloma just got a little more crowded with the US Food and Drug Administration giving the green light to Regeneron Pharmaceuticals’ Lynozyfic
Pink SheetJuly is inextricably linked with Independence Day in the US, but the calendar of applications that are up for Food and Drug Administration actions in July 2025 is notable for the number of novel candi
ScripBayer’s bid to maintain its lead in the anti-vascular endothelial growth factor (VEGF) eye disease space has received a boost with a fresh approval in Europe that extends the intervals between injecti
ScripNektar Therapeutics is making Phase III preparations for rezpegaldesleukin, also known as rezpeg, after the potential pipeline-in-a-product hit its main goal in a mid-stage trial for patients with ato